Ihor Korol practices in primary care in Fort Hood, Tex. Robin H. Baumeister is a biomedical anthropologist in the Department of Epidemiology and Environmental Health at the University at Buffalo in Buffalo, N.Y. The authors have disclosed no potential conflicts of interest, financial or otherwise.
JAAPA. 2023 Sep 1;36(9):1-5. doi: 10.1097/01.JAA.0000937316.70181.ff.
Rheumatoid arthritis (RA) affects about 1% of the world's population and can lead to loss of joint function, reduced mobility, and permanent damage to cartilage and bone. Treatment options for RA primarily include disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, but the development of new drugs has complicated treatment decisions. Weighing treatment options for patients with RA largely depends on three major factors: efficacy, adverse reaction profile, and cost. A review of the literature supports methotrexate monotherapy as the current best-practice model for treating RA, compared with combination therapy of methotrexate and/or other DMARDs.
类风湿关节炎（RA）影响全球约 1%的人口，可导致关节功能丧失、活动能力下降以及软骨和骨的永久性损伤。RA 的治疗选择主要包括甲氨蝶呤等疾病修饰抗风湿药物（DMARDs），但新药的开发使治疗决策变得复杂。RA 患者的治疗选择主要取决于三个主要因素：疗效、不良反应谱和成本。文献综述支持甲氨蝶呤单药治疗作为目前治疗 RA 的最佳实践模式，优于甲氨蝶呤和/或其他 DMARDs 的联合治疗。
